CXCL10 and Graves disease: CXCL10/IP-10 and its receptor, CXCR3, appear to contribute to the pathogeneses of many autoimmune diseases, as the serum and/or tissue expression levels of CXCL10/IP-10 have been reported to be increased in both organ-specific autoimmune diseases, including autoimmune thyroiditis, Graves’ disease, and type I diabetes, and systemic autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis [47].